Results 101 to 110 of about 5,788 (178)

Anti-COVID-19 activity and simple HPLC method for concurrent detection of repurposed drugs in novel binary mixtures. [PDF]

AMB Express
Abd Elsalam MA, Kutkat O, Moatasim Y, Mostafa A, Gaballah M, Elgendy AE, Ali MA, Hadad G, Shabayek S.   +8 more
europepmc   +1 more source

Modeling Predicts Direct-Acting Antiviral Therapy for 5-Weeks May Cure Recent or Chronic Hepatitis C Infection Among People With Undetectable Viral RNA by Day 7. [PDF]

J Infect Dis
Goyal A, Cotler SJ, Matthews GV, Page K, Kushner T, Etzion O, Martinello M, Dahari H.   +7 more
europepmc   +1 more source

Trends in hepatitis C treatment initiation alongside changes in Medicaid policy requirements: Wisconsin, January 2015-December 2022. [PDF]

J Manag Care Spec Pharm
Fantini-Alishahi ML, Ostrenga L, Mitchell K, Huebner J, Westergaard R.   +4 more
europepmc   +1 more source

Nationwide Socioeconomic Evaluation of Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023. [PDF]

J Viral Hepat
Suoh M, Esmaili S, Eslam M, George J.
europepmc   +1 more source

Biochemical and Demographic Factors Affecting Antiviral Treatment Failure in Hepatitis C Patients with Persistent Virologic Response Issues

Pakistan Journal of Medical Research
Background: Worldwide, Hepatitis C virus (HCV) infection is a major public health concern. Twelve weeks following treatment completion, the persistent virologic response is known as SVR.
Sundus Bukhari, Mutayyaba Majeed, Maria Liaqat, Sana Shakeel, Maria Muddassir, Faheem Hadi, Tahir Maqbool   +6 more
doaj  

Direct-Acting Antiviral Therapy and Hepatocellular Carcinoma in Captive Chimpanzees With Long-Standing Chronic Hepatitis C Virus Infection. [PDF]

J Med Virol
Hirata S, Nogami E, Udono T, Fujisawa M, Tanaka Y.   +4 more
europepmc   +1 more source

Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Boonpheng B, Ungprasert P.
europepmc   +1 more source

Antiviral Sesquiterpene Lactones from <i>Laurus nobilis</i> L.: Inhibition of Hepatitis C Virus and Dengue Virus Replication. [PDF]

Viruses
Amen Y, Elsbaey M, Mpekoulis G, Christou E, Tsimpili H, Vassilaki N, Shimizu K, Zoidis G.   +7 more
europepmc   +1 more source

Stevens-Johnson syndrome associated with daclatasvir and sofosbuvir co-therapy in hepatitis C treatment: a rare case report. [PDF]

Ann Med Surg (Lond)
Sajjad W, Rehman UU, Inam A, Alam I, Ghafoor S, Razzaq HD, Khwajakhail T, Gillani SHMUD, Razzaq H, Qamar I, Ali R, Ullah Z.   +11 more
europepmc   +1 more source

A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran. [PDF]

Cost Eff Resour Alloc
Jafari M, Mehdizadeh P, Keshavarz K, Teymourzadeh E, Abyazi MA, Alavian SM, Pouria A.   +6 more
europepmc   +1 more source